Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Pharmaceutical Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.
India Pharmaceutical Market was valued at USD 65.20 Billion in 2024 and is expected to reach USD 106.67 Billion by 2030 with a CAGR of 8.75%
This expansion is largely attributed to the country's robust domestic market and its prominence as a global hub for pharmaceutical manufacturing and innovation. The domestic market benefits from a growing middle class, increased healthcare awareness, and significant government initiatives aimed at improving healthcare access and infrastructure. For instance, programs like the Pradhan Mantri Jan Arogya Yojana (PMJAY) are designed to provide health coverage to economically disadvantaged segments, thereby boosting demand for pharmaceuticals. 
In addition to domestic growth, India has established itself as a major player in the global pharmaceutical industry, particularly through its export of generic medicines. Indian pharmaceutical companies supply over 60% of the world's vaccines and approximately 20% of generic drugs, demonstrating their capability to provide high-quality, cost-effective solutions on a global scale. This position has been reinforced by the country's competitive advantage in the production of generics, which helps meet global healthcare needs at affordable prices.
Despite its impressive growth, the Indian pharmaceutical market faces several challenges that could impact its future trajectory. One of the primary issues is the complex regulatory environment. The Central Drugs Standard Control Organization (CDSCO) is responsible for overseeing drug regulation in India, and while efforts have been made to streamline processes, navigating regulatory requirements remains a challenge for many companies. Compliance with stringent regulations is necessary to ensure the safety and efficacy of pharmaceuticals, but it can also create barriers to entry and increase operational costs.
Another significant challenge is the issue of price controls. The Indian government imposes price controls on essential drugs to make healthcare affordable for the masses. While this policy aims to benefit consumers, it can also affect the profitability of pharmaceutical companies and their capacity to invest in research and development. Price controls can constrain revenue growth and limit the resources available for innovation and expansion.
Key Market Drivers
Growing Prevalence of Chronic Diseases
The Indian pharmaceutical market is witnessing robust growth, driven significantly by the escalating prevalence of chronic diseases. This trend is reshaping the healthcare landscape and creating substantial opportunities for pharmaceutical companies. Chronic diseases such as diabetes, cardiovascular conditions, chronic respiratory diseases, and cancer are becoming increasingly common in India, presenting both challenges and prospects for the pharmaceutical industry.
Rise in Generic Drug Industry
India's pharmaceutical industry stands as a colossal force in the global healthcare landscape, with the generic drug sector playing a pivotal role in its remarkable growth. The rise of the generic drug industry is not merely a facet of the Indian pharmaceutical market but a significant driver shaping its trajectory. This sector's expansion is catalyzing India's emergence as a global hub for affordable and accessible medication, and its influence on the domestic market is profound and multifaceted.
Growing Demand of Biopharmaceuticals
The Indian pharmaceutical industry is witnessing a transformative shift, with biopharmaceuticals emerging as a significant growth driver. This trend reflects a broader global movement towards biologics and advanced therapies, underscoring India's evolving role in the international pharmaceutical landscape. The increasing demand for biopharmaceuticals is reshaping the industry, driven by a confluence of factors that highlight both opportunities and challenges.
The growing focus on biosimilars is also playing a crucial role in the expansion of biopharmaceuticals in India. Biosimilars, which are biologic products highly similar to an already approved reference product, offer a cost-effective alternative to expensive biologic therapies. The Indian pharmaceutical industry is well-positioned to leverage its expertise in generics to develop and market biosimilars, thereby increasing access to essential biologic treatments. This not only meets domestic healthcare needs but also strengthens India's position in the global biopharmaceutical market.
Regional Insights
Based on Region, West India have emerged as the dominating region in the India Pharmaceutical Market in 2024. West India, particularly the states of Maharashtra and Gujarat, benefits from a well-developed industrial infrastructure that has significantly contributed to its dominance in the pharmaceutical market. Maharashtra, with Mumbai as its commercial hub, offers a thriving ecosystem for pharmaceutical companies. The city is home to a substantial number of multinational corporations (MNCs) and domestic pharmaceutical firms, drawn by its advanced infrastructure, availability of skilled talent, and proximity to major ports. This geographical advantage facilitates efficient import and export operations, essential for global pharmaceutical trade.
Gujarat, another key player in West India, has emerged as a pharmaceutical powerhouse due to its conducive business environment and government policies that favor industrial growth. The state government has implemented several initiatives to attract pharmaceutical investments, including offering incentives for setting up manufacturing units and research facilities. Gujarat's well-established chemical and pharmaceutical industrial parks, such as the Gujarat Industrial Development Corporation (GIDC) estates, provide companies with the necessary infrastructure and logistical support to thrive.
The presence of a strong network of research and development (R&D) facilities further cements West India's position in the pharmaceutical sector. The region is home to numerous R&D centers and institutions that foster innovation and support pharmaceutical development. Collaboration between academia and industry in West India has led to significant advancements in drug development and manufacturing processes. The region's focus on R&D is crucial in maintaining a competitive edge in the global pharmaceutical market, particularly in the development of generic drugs and specialty pharmaceuticals.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 85 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $65.2 Billion |
| Forecasted Market Value (USD) by 2030 | $106.67 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | India |
Key Market Players
- Sun Pharmaceutical Industries Limited
- Divis Laboratories Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceutical Limited
- Zydus Lifesciences Limited
- Abbott India Limited
- Alkem Laboratories Limited
- Biocon Limited
- Lupin Limited
- Mankind Pharma Limited
- Intas Pharmaceuticals Limited
- Piramal Enterprises Limited
- Wockhardt Limited
- Glenmark Pharma Limited
Report Scope
India Pharmaceutical Market, By Type:
- Pharmaceutical Drugs
- Biologics
India Pharmaceutical Market, By Drug Classification:
- Branded Drugs
- Generic Drugs
India Pharmaceutical Market, By Mode of Purchase:
- Prescription-Based Drugs
- Over-the-counter Drugs
India Pharmaceutical Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
India Pharmaceutical Market, By Region:
- North India
- East India
- West India
- South India
For more information about this report visit https://www.researchandmarkets.com/r/3e7aba
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
